The global Cardiac Safety Assessment Services market size is predicted to grow from US$ 798 million in 2025 to US$ 1458 million in 2031; it is expected to grow at a CAGR of 10.6% from 2025 to 2031.
Cardiac safety assessment is an important, animal or animal tissue-based experimental procedure that must be considered before entering into clinical trials. In the past few years, some drugs that have been put into clinical use have had to be withdrawn from the market or their approval has been delayed because of their potential cardiotoxicity or causing severe cardiac arrhythmias.
Drug-induced cardiotoxicity is one of the main reasons for new drugs to be discontinued or removed from the market. Therefore, cardiac safety assessment is a mandatory experimental procedure for various new drugs before entering clinical trials. At present, "hERG assay (hERG Assay)" (hERG assay is to evaluate the inhibitory effect of drugs on hERc current in stable expression cell lines) is considered to be the existing gold standard for preclinical cardiac safety assessment, and it is also the necessary information for new drug approval required by FDA.
Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market, and current trends show that top pharmaceutical companies are increasing R&D efficiency through substantial R&D investments to achieve long-term ROI and through collaborative R&D efforts, which will help increase demand for preclinical and clinical services, including cardiac safety assessments.
The 鈥淐ardiac Safety Assessment Services Industry Forecast鈥� looks at past sales and reviews total world Cardiac Safety Assessment Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Cardiac Safety Assessment Services sales for 2025 through 2031. With Cardiac Safety Assessment Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cardiac Safety Assessment Services industry.
This Insight Report provides a comprehensive analysis of the global Cardiac Safety Assessment Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cardiac Safety Assessment Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cardiac Safety Assessment Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cardiac Safety Assessment Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cardiac Safety Assessment Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Cardiac Safety Assessment Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Preclinical Cardiac Safety Assessment
Clinical Cardiac Safety Assessment
Segmentation by Application:
Commissioned Research Institute
Pharmaceutical Company
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Laboratory Corporation of America Holdings
Metrion
Clario
Banook Group
Iqvia
Celerion
Certara
Biotrial
Medpace
Physiostim
Richmond Pharmacology
Ncardia
Pharmaceutical Product Development Llc.
Reaction Biology
Eurofins Discovery
Altasciences
NEXEL
charles river
Scottish Institute of Electrophysiology
Ronovation Biotech
Elixir Clinical Research
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Cardiac Safety Assessment Services 麻豆原创 Size (2020-2031)
2.1.2 Cardiac Safety Assessment Services 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Cardiac Safety Assessment Services by Country/Region (2020, 2024 & 2031)
2.2 Cardiac Safety Assessment Services Segment by Type
2.2.1 Preclinical Cardiac Safety Assessment
2.2.2 Clinical Cardiac Safety Assessment
2.3 Cardiac Safety Assessment Services 麻豆原创 Size by Type
2.3.1 Cardiac Safety Assessment Services 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Cardiac Safety Assessment Services 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Cardiac Safety Assessment Services Segment by Application
2.4.1 Commissioned Research Institute
2.4.2 Pharmaceutical Company
2.4.3 Others
2.5 Cardiac Safety Assessment Services 麻豆原创 Size by Application
2.5.1 Cardiac Safety Assessment Services 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Cardiac Safety Assessment Services 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Cardiac Safety Assessment Services 麻豆原创 Size by Player
3.1 Cardiac Safety Assessment Services 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Cardiac Safety Assessment Services Revenue by Player (2020-2025)
3.1.2 Global Cardiac Safety Assessment Services Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Cardiac Safety Assessment Services Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cardiac Safety Assessment Services by Region
4.1 Cardiac Safety Assessment Services 麻豆原创 Size by Region (2020-2025)
4.2 Global Cardiac Safety Assessment Services Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cardiac Safety Assessment Services 麻豆原创 Size Growth (2020-2025)
4.4 APAC Cardiac Safety Assessment Services 麻豆原创 Size Growth (2020-2025)
4.5 Europe Cardiac Safety Assessment Services 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Cardiac Safety Assessment Services 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Cardiac Safety Assessment Services 麻豆原创 Size by Country (2020-2025)
5.2 Americas Cardiac Safety Assessment Services 麻豆原创 Size by Type (2020-2025)
5.3 Americas Cardiac Safety Assessment Services 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cardiac Safety Assessment Services 麻豆原创 Size by Region (2020-2025)
6.2 APAC Cardiac Safety Assessment Services 麻豆原创 Size by Type (2020-2025)
6.3 APAC Cardiac Safety Assessment Services 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cardiac Safety Assessment Services 麻豆原创 Size by Country (2020-2025)
7.2 Europe Cardiac Safety Assessment Services 麻豆原创 Size by Type (2020-2025)
7.3 Europe Cardiac Safety Assessment Services 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cardiac Safety Assessment Services by Region (2020-2025)
8.2 Middle East & Africa Cardiac Safety Assessment Services 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Cardiac Safety Assessment Services 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Cardiac Safety Assessment Services 麻豆原创 Forecast
10.1 Global Cardiac Safety Assessment Services Forecast by Region (2026-2031)
10.1.1 Global Cardiac Safety Assessment Services Forecast by Region (2026-2031)
10.1.2 Americas Cardiac Safety Assessment Services Forecast
10.1.3 APAC Cardiac Safety Assessment Services Forecast
10.1.4 Europe Cardiac Safety Assessment Services Forecast
10.1.5 Middle East & Africa Cardiac Safety Assessment Services Forecast
10.2 Americas Cardiac Safety Assessment Services Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Cardiac Safety Assessment Services Forecast
10.2.2 Canada 麻豆原创 Cardiac Safety Assessment Services Forecast
10.2.3 Mexico 麻豆原创 Cardiac Safety Assessment Services Forecast
10.2.4 Brazil 麻豆原创 Cardiac Safety Assessment Services Forecast
10.3 APAC Cardiac Safety Assessment Services Forecast by Region (2026-2031)
10.3.1 China Cardiac Safety Assessment Services 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Cardiac Safety Assessment Services Forecast
10.3.3 Korea 麻豆原创 Cardiac Safety Assessment Services Forecast
10.3.4 Southeast Asia 麻豆原创 Cardiac Safety Assessment Services Forecast
10.3.5 India 麻豆原创 Cardiac Safety Assessment Services Forecast
10.3.6 Australia 麻豆原创 Cardiac Safety Assessment Services Forecast
10.4 Europe Cardiac Safety Assessment Services Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Cardiac Safety Assessment Services Forecast
10.4.2 France 麻豆原创 Cardiac Safety Assessment Services Forecast
10.4.3 UK 麻豆原创 Cardiac Safety Assessment Services Forecast
10.4.4 Italy 麻豆原创 Cardiac Safety Assessment Services Forecast
10.4.5 Russia 麻豆原创 Cardiac Safety Assessment Services Forecast
10.5 Middle East & Africa Cardiac Safety Assessment Services Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Cardiac Safety Assessment Services Forecast
10.5.2 South Africa 麻豆原创 Cardiac Safety Assessment Services Forecast
10.5.3 Israel 麻豆原创 Cardiac Safety Assessment Services Forecast
10.5.4 Turkey 麻豆原创 Cardiac Safety Assessment Services Forecast
10.6 Global Cardiac Safety Assessment Services Forecast by Type (2026-2031)
10.7 Global Cardiac Safety Assessment Services Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Cardiac Safety Assessment Services Forecast
11 Key Players Analysis
11.1 Laboratory Corporation of America Holdings
11.1.1 Laboratory Corporation of America Holdings Company Information
11.1.2 Laboratory Corporation of America Holdings Cardiac Safety Assessment Services Product Offered
11.1.3 Laboratory Corporation of America Holdings Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Laboratory Corporation of America Holdings Main Business Overview
11.1.5 Laboratory Corporation of America Holdings Latest Developments
11.2 Metrion
11.2.1 Metrion Company Information
11.2.2 Metrion Cardiac Safety Assessment Services Product Offered
11.2.3 Metrion Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Metrion Main Business Overview
11.2.5 Metrion Latest Developments
11.3 Clario
11.3.1 Clario Company Information
11.3.2 Clario Cardiac Safety Assessment Services Product Offered
11.3.3 Clario Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Clario Main Business Overview
11.3.5 Clario Latest Developments
11.4 Banook Group
11.4.1 Banook Group Company Information
11.4.2 Banook Group Cardiac Safety Assessment Services Product Offered
11.4.3 Banook Group Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Banook Group Main Business Overview
11.4.5 Banook Group Latest Developments
11.5 Iqvia
11.5.1 Iqvia Company Information
11.5.2 Iqvia Cardiac Safety Assessment Services Product Offered
11.5.3 Iqvia Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Iqvia Main Business Overview
11.5.5 Iqvia Latest Developments
11.6 Celerion
11.6.1 Celerion Company Information
11.6.2 Celerion Cardiac Safety Assessment Services Product Offered
11.6.3 Celerion Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Celerion Main Business Overview
11.6.5 Celerion Latest Developments
11.7 Certara
11.7.1 Certara Company Information
11.7.2 Certara Cardiac Safety Assessment Services Product Offered
11.7.3 Certara Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Certara Main Business Overview
11.7.5 Certara Latest Developments
11.8 Biotrial
11.8.1 Biotrial Company Information
11.8.2 Biotrial Cardiac Safety Assessment Services Product Offered
11.8.3 Biotrial Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Biotrial Main Business Overview
11.8.5 Biotrial Latest Developments
11.9 Medpace
11.9.1 Medpace Company Information
11.9.2 Medpace Cardiac Safety Assessment Services Product Offered
11.9.3 Medpace Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Medpace Main Business Overview
11.9.5 Medpace Latest Developments
11.10 Physiostim
11.10.1 Physiostim Company Information
11.10.2 Physiostim Cardiac Safety Assessment Services Product Offered
11.10.3 Physiostim Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Physiostim Main Business Overview
11.10.5 Physiostim Latest Developments
11.11 Richmond Pharmacology
11.11.1 Richmond Pharmacology Company Information
11.11.2 Richmond Pharmacology Cardiac Safety Assessment Services Product Offered
11.11.3 Richmond Pharmacology Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Richmond Pharmacology Main Business Overview
11.11.5 Richmond Pharmacology Latest Developments
11.12 Ncardia
11.12.1 Ncardia Company Information
11.12.2 Ncardia Cardiac Safety Assessment Services Product Offered
11.12.3 Ncardia Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Ncardia Main Business Overview
11.12.5 Ncardia Latest Developments
11.13 Pharmaceutical Product Development Llc.
11.13.1 Pharmaceutical Product Development Llc. Company Information
11.13.2 Pharmaceutical Product Development Llc. Cardiac Safety Assessment Services Product Offered
11.13.3 Pharmaceutical Product Development Llc. Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Pharmaceutical Product Development Llc. Main Business Overview
11.13.5 Pharmaceutical Product Development Llc. Latest Developments
11.14 Reaction Biology
11.14.1 Reaction Biology Company Information
11.14.2 Reaction Biology Cardiac Safety Assessment Services Product Offered
11.14.3 Reaction Biology Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Reaction Biology Main Business Overview
11.14.5 Reaction Biology Latest Developments
11.15 Eurofins Discovery
11.15.1 Eurofins Discovery Company Information
11.15.2 Eurofins Discovery Cardiac Safety Assessment Services Product Offered
11.15.3 Eurofins Discovery Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Eurofins Discovery Main Business Overview
11.15.5 Eurofins Discovery Latest Developments
11.16 Altasciences
11.16.1 Altasciences Company Information
11.16.2 Altasciences Cardiac Safety Assessment Services Product Offered
11.16.3 Altasciences Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Altasciences Main Business Overview
11.16.5 Altasciences Latest Developments
11.17 NEXEL
11.17.1 NEXEL Company Information
11.17.2 NEXEL Cardiac Safety Assessment Services Product Offered
11.17.3 NEXEL Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 NEXEL Main Business Overview
11.17.5 NEXEL Latest Developments
11.18 charles river
11.18.1 charles river Company Information
11.18.2 charles river Cardiac Safety Assessment Services Product Offered
11.18.3 charles river Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 charles river Main Business Overview
11.18.5 charles river Latest Developments
11.19 Scottish Institute of Electrophysiology
11.19.1 Scottish Institute of Electrophysiology Company Information
11.19.2 Scottish Institute of Electrophysiology Cardiac Safety Assessment Services Product Offered
11.19.3 Scottish Institute of Electrophysiology Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Scottish Institute of Electrophysiology Main Business Overview
11.19.5 Scottish Institute of Electrophysiology Latest Developments
11.20 Ronovation Biotech
11.20.1 Ronovation Biotech Company Information
11.20.2 Ronovation Biotech Cardiac Safety Assessment Services Product Offered
11.20.3 Ronovation Biotech Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Ronovation Biotech Main Business Overview
11.20.5 Ronovation Biotech Latest Developments
11.21 Elixir Clinical Research
11.21.1 Elixir Clinical Research Company Information
11.21.2 Elixir Clinical Research Cardiac Safety Assessment Services Product Offered
11.21.3 Elixir Clinical Research Cardiac Safety Assessment Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 Elixir Clinical Research Main Business Overview
11.21.5 Elixir Clinical Research Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.